{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=3", "query": { "intervention": "Placebo SC Injection", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 833, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T19:12:34.881Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00265083", "title": "A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spondylitis, Ankylosing" ], "interventions": [ { "name": "golimumab", "type": "BIOLOGICAL" }, { "name": "Golimumab (CNTO 148); placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 356, "start_date": "2005-12", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2013-07-19", "last_synced_at": "2026-10-28T19:12:34.881Z", "location_count": 11, "location_summary": "Paradise Valley, Arizona • Los Angeles, California • San Francisco, California + 8 more", "locations": [ { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00265083" }, { "nct_id": "NCT06557772", "title": "A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coeliac Disease", "Celiac Disease" ], "interventions": [ { "name": "Amlitelimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "SIGE", "type": "DIETARY_SUPPLEMENT" }, { "name": "Gluten-free product (GFP)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 229, "start_date": "2024-08-29", "completion_date": "2029-04-10", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-28T19:12:34.881Z", "location_count": 35, "location_summary": "Scottsdale, Arizona • Arcadia, California • Lancaster, California + 32 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Oxnard", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06557772" }, { "nct_id": "NCT03770728", "title": "Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Efpeglenatide SAR439977", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Background therapy: Metformin alone or in combination with SU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2019-08-01", "completion_date": "2020-12-27", "has_results": true, "last_update_posted_date": "2021-12-02", "last_synced_at": "2026-10-28T19:12:34.881Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03770728" }, { "nct_id": "NCT03312907", "title": "A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Belimumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Rituximab-placebo", "type": "DRUG" }, { "name": "Standard therapy (Including Immunosuppressants)", "type": "DRUG" }, { "name": "Standard therapy (Excluding Immunosuppressants)", "type": "DRUG" }, { "name": "Steroid Taper", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 292, "start_date": "2018-03-01", "completion_date": "2021-07-07", "has_results": true, "last_update_posted_date": "2025-02-18", "last_synced_at": "2026-10-28T19:12:34.881Z", "location_count": 28, "location_summary": "Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Mesa", "state": "California" }, { "city": "San Leandro", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03312907" }, { "nct_id": "NCT04048135", "title": "A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NASH" ], "interventions": [ { "name": "Pegozafermin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "89bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 101, "start_date": "2019-07-29", "completion_date": "2022-01-19", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-28T19:12:34.881Z", "location_count": 25, "location_summary": "Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more", "locations": [ { "city": "Madison", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04048135" }, { "nct_id": "NCT01142726", "title": "Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Abatacept placebo", "type": "DRUG" }, { "name": "Methotrexate placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 511, "start_date": "2010-12", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-01-14", "last_synced_at": "2026-10-28T19:12:34.881Z", "location_count": 15, "location_summary": "Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01142726" }, { "nct_id": "NCT03298061", "title": "Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Churg-Strauss Syndrome", "Eosinophilic Granulomatosis With Polyangiitis" ], "interventions": [ { "name": "Mepolizumab", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2015-04-14", "completion_date": "2023-02-16", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-28T19:12:34.881Z", "location_count": 14, "location_summary": "Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 10 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03298061" }, { "nct_id": "NCT03746522", "title": "Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bardet Biedl Syndrome (BBS)", "Alström Syndrome (AS)" ], "interventions": [ { "name": "Setmelanotide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhythm Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 52, "start_date": "2018-11-23", "completion_date": "2021-03-08", "has_results": true, "last_update_posted_date": "2023-12-01", "last_synced_at": "2026-10-28T19:12:34.881Z", "location_count": 6, "location_summary": "San Diego, California • Springfield, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03746522" }, { "nct_id": "NCT04180488", "title": "Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "non sedating H1-antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "6 Years to 80 Years" }, "enrollment_count": 397, "start_date": "2019-12-11", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-10-28T19:12:34.881Z", "location_count": 16, "location_summary": "Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Sweetwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04180488" }, { "nct_id": "NCT01855789", "title": "A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tocilizumab (TCZ)", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Placebo (PBO)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 718, "start_date": "2013-11-07", "completion_date": "2016-10-14", "has_results": true, "last_update_posted_date": "2017-12-26", "last_synced_at": "2026-10-28T19:12:34.881Z", "location_count": 155, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 126 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01855789" } ] }